Judith A. Aberg, MD, FIDSA, FACP

Judith A. Aberg, MD, FIDSA, FACP

ICAHN School of Medicine at Mount Sinai

George Baehr Professor of Medicine
Chief, Division of Infectious Diseases
ICAHN School of Medicine at Mount Sinai
New York, New York

Committees and Organizations

  • Past Chair, HIV Medicine Association
  • Past Executive Board Member , HIV Medicine Association and liaison to Board for Infectious Diseases Society of America
  • Past Chair, New York State AIDS Institute Medical Care Committee
  • Co-Chair of the National Committee for Quality Assurance (NCQA), AMA, HRSA, HIVMA Consortium of HIV Performance Measures
  • Member, DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Honors and Awards

  • Linda Lauberstein Award for Clinical Excellence, NY State Dept of Health/AIDS Institute (2008)
  • Constance B. Wofsy Women\’s Health Investigator Award, AIDS Clinical Trials Group (2006)
  • AIDS Foundation of St. Louis: Red Ribbon Award (2004)
  • John Carey Young Investigator Award, AIDS Clinical Trials Group (2000)


  • Pennsylvania State University, College of Medicine, MD (1990)
  • Cleveland Clinic Educational Foundation, Internal Medicine Residency (1990-1993); Chief Medical Resident (1993-1994)
  • Washington University School of Medicine, Department of Infectious Diseases, Fellow (1994-1996)

Selected Publications

  1. Wang L, Krebs E, Min JE, Nijhawan A, Somboonwit C, Aberg J, Moore RD, Gebo K, Nosyk B, for the HIV Research Network. Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. The Lancet HIV. 2019
  2. Radwan D, Cachay E, Falade-Nwulia O, Moore RD, Westergaard R, Mathews WC, Aberg J, Cheever L, Gebo KA; HIV Research Network. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):559-567
  3. Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Am Heart J. 2019 Mar 4;212:23-35
  4. Rusley JC, Monroe A, Matson P, Gebo KA, Nonyane BAS, Minkovitz CS, Agwu A, Emerson M, Moore R, Rutstein R, Aberg J, Nijhawan A, Boswell S, Sanders R; HIV Research Network. Discontinuity in Medicaid Coverage Among Young Adults with HIV AIDS Patient Care STDS. 2019 Mar;33(3):89-92
  5. Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, Gaur AH, Mathews WC, Beil R, Korthuis PT, Nijhawan AE, Rutstein RM, Agwu AL; HIV Research Network. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research NetworkHIV Med. 2019 Feb;20(2):169-174
  6. Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med. 2018 Oct 3;10(461).
  7. Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep;35:58-66
  8. Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA. Anogenital Human Papillomavirus Virus DNA and Sustained Response to the Quadrivalent HPV Vaccine in Women Living with HIV-1. Papillomavirus Res. 2018 Dec;6:15-21
  9. Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332. Medicine 2018 Jun;97(22):e10955
  10. Monroe AK, Myint L, Rutstein R, Aberg J, Boswell S, Agwu A, Gebo K, Moore R; HIV Research Network. Factors Associated with Gaps in Medicaid Enrollment among People with HIV and the Effect of Gaps on Viral Suppression. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):413-420
  11. Gandhi V, Nurutdinova D, Milunka Kojic E, Aberg JA. Human Immunodeficiency Virus Medicine Association Pain Management Guidelines Needed to Curb Opioid Epidemic. Clin Infect Dis. 2018 Mar 19;66(7):1152-1153
  12. Aberg JA, Blankson J, Marrazzo J, Adimora AA. Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities. J Infect Dis. 2017 Sep 15;216(suppl_5):S606-S610
  13. George V, Harrison L, Roach M, Li XD, Tierney C, Fischl MA, Aberg J, Tebas P, Asmuth DM, Pollard RB, Godfrey C, Pahwa S; AIDS Clinical Trials Group A5202 Study Team. Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome. J Infect Dis. 2017; 16(9): 1159-63
  14. Dittmer DP, Tamburro K, Chen H, Lee A, Sanders MK, Wade TA, Napravnik S, Webster-Cyriaque J, Ghannoum M, Shiboski CH, Aberg JA. Oral shedding of Herpesviruses in HIV+ patients with varying degrees of immune status. AIDS. 2017 Sep 24;31(15):2077-2084
  15. Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017: Jul;4(7):e284-e294.
  16. O\’Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2017;4(1):ofw278
  17. Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, Lederman MM, Klingman KL, Aberg JA. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). J Clin Lipidol. 2017;11(1):61-69
  18. Gaisa M, Ita-Nagy F, Sigel K, Arens Y, Hennessy MA, Rodriguez-Caprio G, Mullen M, Aberg JA, Cespedes M. High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines. Clin Infect Dis. 2017 Feb 1;64(3):289-294
  19. Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, McCurdy Pate M, Aberg JA, Zanni MV, Grinspoon SK. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 Mar 27;31(6):797-806
  20. Gusella GL, Teixeira A, Aberg J, Uversky VN, Mosoian A. Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways. PLoS One. 2016 Jun 16;11(6):e0156486
  21. Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AM, Aberg JA. Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332. Inflammation. 2016;39(4):1354-62
  22. Teixeira A, Yen B, Gusella GL, Thomas AG, Mullen MP, Aberg J, Chen X, Hoshida Y, van Bakel H, Schadt E, Basler CF, García-Sastre A, Mosoian A. Prothymosin α Variants Isolated From CD8+ T Cells and Cervicovaginal Fluid Suppress HIV-1 Replication Through Type I Interferon Induction. J Infect Dis. 2015 May 1;211(9):1467-75
  23. Phelan, Joan A; Abrams, William R; Norman, Robert G; Li, Yihong; Laverty, Maura; Corby, Patricia M; Nembhard, Jason; Neri, Dinah; Barber, Cheryl A; Aberg, Judith A; Fisch, Gene S; Poles, Michael A; Malamud, Daniel. \’Design Aspects of a Case-Control Clinical Investigation of the Effect of HIV on Oral and Gastrointestinal Soluble Innate Factors and Microbes\’. PLoS one. 2014; 9(11): Nov 19;9(11):e112901 (PMC 4237510)
  24. Myerson M, Malvestutto C and Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol 2015 Sep;55(9):957-74
  25. Shiboski CH, Chen H, Secours R, Lee A, Webster-Cyriaque J, Ghannoum M, Evans S, Bernard D, Reznik D, Dittmer DP, Hosey L, Sévère P, Aberg JA. High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. PLoS One. 2015 Jul 6;10(7):e0131001 (PMC4492974
  26. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):1-10
  27. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):e1-34.
  28. Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA. Virologic and Serologic Outcomes of Mono vs. Dual HBV Therapy and Characterization of HIV/HBV Coinfection in a US Cohort. J Acquir Immune Defic Syndr. 2014;66(2):172-80
  29. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. Clin Infect Dis. 2014: 1;59(1):127-35. (PMC4305143)
  30. Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-Perception of HIV Risk and Candidacy for Pre-Exposure Prophylaxis Among Men Who Have Sex with Men Testing for HIV at Commercial Sex Venues in New York City. LGBT Health 2014;1(3):1-7
  31. Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team. A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2014;66(4):399-406
  32. Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-Producing Effector and Regulatory Human T Cells from Lineage-Committed Naive Precursors. J Immunol. 2014; 193(3):1047-54
  33. Günthard HFG, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral Treatment of Adult HIV-1 Infection 2014 Recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312(4):410-25
  34. Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA. Lack of pharmacokinetic interactions between Pitavastatin and Efavirenz or Darunavir/Ritonavir. J Acquir Immune Defic Syndr. 2014; 67(4):390-6
  35. Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010;4:279-287.
  36. Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010;50:1041-1052.
  37. Horberg MA, Aberg JA, Cheever LW, Renner P, O\’Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. 2010;51:732-738.
  38. Malvestutto CD, Aberg JA. Coronary heart disease in people infected with HIV. Cleve Clin J Med. 2010;77:547-556.
  39. Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010;201:1298-1302.
  40. McComsey GA, Walker UA, Budhathoki CB, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS. 2010;24:2507-2515.
  41. Overton ET, Kang M, Peters MG, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010;28:5597-5604.
  42. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International Antiviral Society–USA panel. JAMA. 2010;304:321-333.
  43. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781-1784.
  44. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. JAIDS. 2009;50:54-64.
  45. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009;38:207-222.
  46. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-681.
  47. Daskalakis D, Silvera R, Bernstein K, et al. Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis. 2009;48:1609-1616.
  48. Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward–a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009;48:1335-1344.
  49. Tsibris AM, Paredes R, Chadburn A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009;48:642-649.